Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ocugen Inc's Business Segments
Ocugen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable203.1%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 3 | 203.1% |
Description of Ocugen Inc
Ocugen Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania, that is focused on discovering, developing, and commercializing transformative therapies for rare and underserved eye diseases. The company is committed to improving the lives of patients worldwide by addressing unmet medical needs in ophthalmology.
Ocugen's primary focus lies in developing gene therapies for inherited retinal diseases (IRDs) and Dry Age-Related Macular Degeneration (Dry-AMD). These are debilitating conditions that can result in vision loss or blindness, and there are currently limited treatment options available. By leveraging their deep understanding of genetics, molecular biology, and ocular diseases, Ocugen aims to bring innovative solutions to patients suffering from these conditions.
One of the key areas of expertise for Ocugen is gene therapy. Their flagship product candidate, OCU400, is a gene therapy designed to treat IRDs caused by mutations in the RPGR gene. It aims to restore the functional RPGR protein in the retinal cells, thereby slowing down or stopping the progression of the disease. Ocugen is working diligently to advance OCU400 through clinical trials, with the ultimate goal of obtaining regulatory approval and making it available to patients who desperately need it.
In addition to gene therapy, Ocugen is also actively involved in developing biologic therapies for Dry-AMD. Their lead product candidate in this area is OCU200, which utilizes a novel mechanism to address the underlying cause of Dry-AMD. OCU200 aims to restore the balance of the complement system in the eye, which is dysregulated in patients with Dry-AMD. By doing so, it has the potential to not only slow down disease progression but also improve visual acuity in affected individuals.
Beyond their product pipeline, Ocugen actively pursues collaborations and partnerships to leverage their scientific expertise and technologies. They have entered into strategic alliances with various organizations, including academic institutions and pharmaceutical companies, to accelerate the development of novel therapies for eye diseases. These collaborations enable Ocugen to tap into additional knowledge and resources, helping them to bring their groundbreaking treatments to market faster.
Ocugen is committed to advancing the field of ophthalmology by investing in research and development. They continuously evaluate new opportunities and technologies that can enhance their product portfolio and expand their reach. By engaging in strategic research initiatives and clinical trials, they aim to uncover new therapeutic options for various eye disorders, ultimately benefiting patients worldwide.
In summary, Ocugen Inc. is a biopharmaceutical company dedicated to developing transformative therapies for rare and underserved eye diseases. With a strong focus on gene and biologic therapies, they are working tirelessly to bring hope to patients suffering from inherited retinal diseases and Dry-AMD. Through collaborations and strategic alliances, Ocugen continues to innovate and advance the field of ophthalmology, with the ultimate goal of improving the lives of individuals affected by these debilitating conditions.
Ocugen's primary focus lies in developing gene therapies for inherited retinal diseases (IRDs) and Dry Age-Related Macular Degeneration (Dry-AMD). These are debilitating conditions that can result in vision loss or blindness, and there are currently limited treatment options available. By leveraging their deep understanding of genetics, molecular biology, and ocular diseases, Ocugen aims to bring innovative solutions to patients suffering from these conditions.
One of the key areas of expertise for Ocugen is gene therapy. Their flagship product candidate, OCU400, is a gene therapy designed to treat IRDs caused by mutations in the RPGR gene. It aims to restore the functional RPGR protein in the retinal cells, thereby slowing down or stopping the progression of the disease. Ocugen is working diligently to advance OCU400 through clinical trials, with the ultimate goal of obtaining regulatory approval and making it available to patients who desperately need it.
In addition to gene therapy, Ocugen is also actively involved in developing biologic therapies for Dry-AMD. Their lead product candidate in this area is OCU200, which utilizes a novel mechanism to address the underlying cause of Dry-AMD. OCU200 aims to restore the balance of the complement system in the eye, which is dysregulated in patients with Dry-AMD. By doing so, it has the potential to not only slow down disease progression but also improve visual acuity in affected individuals.
Beyond their product pipeline, Ocugen actively pursues collaborations and partnerships to leverage their scientific expertise and technologies. They have entered into strategic alliances with various organizations, including academic institutions and pharmaceutical companies, to accelerate the development of novel therapies for eye diseases. These collaborations enable Ocugen to tap into additional knowledge and resources, helping them to bring their groundbreaking treatments to market faster.
Ocugen is committed to advancing the field of ophthalmology by investing in research and development. They continuously evaluate new opportunities and technologies that can enhance their product portfolio and expand their reach. By engaging in strategic research initiatives and clinical trials, they aim to uncover new therapeutic options for various eye disorders, ultimately benefiting patients worldwide.
In summary, Ocugen Inc. is a biopharmaceutical company dedicated to developing transformative therapies for rare and underserved eye diseases. With a strong focus on gene and biologic therapies, they are working tirelessly to bring hope to patients suffering from inherited retinal diseases and Dry-AMD. Through collaborations and strategic alliances, Ocugen continues to innovate and advance the field of ophthalmology, with the ultimate goal of improving the lives of individuals affected by these debilitating conditions.
Ocugen Inc. is a biopharmaceutical company that focuses on innovative therapies aimed at addressing rare and underserved ocular diseases. As a player in the ophthalmic therapeutics field, Ocugen has strategically segmented its product offerings and services into distinct categories that cater to various ocular health challenges.
Segments
1. Gene Therapies:
Ocugen’s gene therapy segment is dedicated to developing therapies for inherited retinal diseases (IRDs). This includes conditions such as:
- Retinitis Pigmentosa: A genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells.
- Usher Syndrome: A condition that involves hearing loss and visual impairment caused by mutations that affect both auditory and retinal cells.
- Stargardt Disease: A form of juvenile macular degeneration that leads to significant visual impairment.
The core objective of these gene therapies is to directly address the genetic factors causing these diseases. By correcting or compensating for the underlying mutations, Ocugen aims to provide patients with a potential cure or significant improvement in visual function. An example of their efforts in this segment is OCU400, which focuses on the NR2E3 gene mutation.
2. Biologics:
Ocugens biologics segment includes therapies derived from biological sources, which are often protein-based. This area predominantly targets:
- Diabetic Macular Edema (DME): A complication arising from diabetes that leads to swelling in the macula, resulting in vision distortion and impairment.
A leading product in this segment is OCU200, which aims to mitigate the inflammatory and vascular dysfunction that characterizes diabetic macular edema. These biologic products are designed to interact with the immune response or other biological pathways, thereby addressing the underlying causes of the disease.
3. Small Molecules:
The small molecules segment at Ocugen encompasses the development of low-molecular-weight drug candidates aimed at various ocular conditions. Potential applications include:
- Dry Eye Disease: A common and often chronic condition characterized by inflammation and damage of the ocular surface, leading to discomfort and visual disturbances.
- Glaucoma: A group of eye diseases that damage the optic nerve and can lead to loss of vision, often related to increased intraocular pressure.
- Age-Related Macular Degeneration (AMD): A leading cause of vision loss in older adults that affects the macula, the region of the retina responsible for sharp central vision.
These candidates are designed to interact with specific biological targets, potentially slowing disease progression or alleviating symptoms.
Products and Services
1. OCU400:
OCU400 represents Ocugens flagship gene therapy candidate developed to treat genetically driven blindness linked to mutations in the NR2E3 gene. Currently in preclinical development, OCU400 has exhibited encouraging results in animal models, with the potential to restore visual function and enhance the quality of life for affected individuals.
2. OCU200:
This biologic candidate focuses on diabetic macular edema, addressing both inflammation and vascular alterations linked to diabetes. Like OCU400, OCU200 is in the preclinical stage, where it is undergoing testing for efficacy and safety to pave the way for future clinical trials.
3. Small Molecule Candidates:
Ocugen is advancing various small molecule candidates through its research and development pipeline. These include treatments not only for dry eye disease and glaucoma but also for a spectrum of other ocular conditions. The precise mechanisms of action for these small molecules are tailored to target the intricate pathways involved in each disease process to maximize therapeutic effects.
4. Research and Development Services:
In addition to its proprietary therapeutic candidates, Ocugen provides comprehensive research and development services aimed at partnering with other organizations. These services can range from preclinical development and clinical trial management to regulatory assistance and manufacturing solutions, facilitating the overall drug development process for both internal and external projects.
Conclusion
Ocugen Inc. stands out in the biopharmaceutical landscape with its focused approach to addressing rare and challenging ocular diseases through gene therapies, biologics, and small molecules. With innovative product candidates and supportive services, Ocugen is committed to improving patient outcomes and pioneering advancements in ocular health. As advancements in their development pipeline continue to progress, Ocugen remains dedicated to meeting the significant unmet needs within the field of ophthalmology.
Segments
1. Gene Therapies:
Ocugen’s gene therapy segment is dedicated to developing therapies for inherited retinal diseases (IRDs). This includes conditions such as:
- Retinitis Pigmentosa: A genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells.
- Usher Syndrome: A condition that involves hearing loss and visual impairment caused by mutations that affect both auditory and retinal cells.
- Stargardt Disease: A form of juvenile macular degeneration that leads to significant visual impairment.
The core objective of these gene therapies is to directly address the genetic factors causing these diseases. By correcting or compensating for the underlying mutations, Ocugen aims to provide patients with a potential cure or significant improvement in visual function. An example of their efforts in this segment is OCU400, which focuses on the NR2E3 gene mutation.
2. Biologics:
Ocugens biologics segment includes therapies derived from biological sources, which are often protein-based. This area predominantly targets:
- Diabetic Macular Edema (DME): A complication arising from diabetes that leads to swelling in the macula, resulting in vision distortion and impairment.
A leading product in this segment is OCU200, which aims to mitigate the inflammatory and vascular dysfunction that characterizes diabetic macular edema. These biologic products are designed to interact with the immune response or other biological pathways, thereby addressing the underlying causes of the disease.
3. Small Molecules:
The small molecules segment at Ocugen encompasses the development of low-molecular-weight drug candidates aimed at various ocular conditions. Potential applications include:
- Dry Eye Disease: A common and often chronic condition characterized by inflammation and damage of the ocular surface, leading to discomfort and visual disturbances.
- Glaucoma: A group of eye diseases that damage the optic nerve and can lead to loss of vision, often related to increased intraocular pressure.
- Age-Related Macular Degeneration (AMD): A leading cause of vision loss in older adults that affects the macula, the region of the retina responsible for sharp central vision.
These candidates are designed to interact with specific biological targets, potentially slowing disease progression or alleviating symptoms.
Products and Services
1. OCU400:
OCU400 represents Ocugens flagship gene therapy candidate developed to treat genetically driven blindness linked to mutations in the NR2E3 gene. Currently in preclinical development, OCU400 has exhibited encouraging results in animal models, with the potential to restore visual function and enhance the quality of life for affected individuals.
2. OCU200:
This biologic candidate focuses on diabetic macular edema, addressing both inflammation and vascular alterations linked to diabetes. Like OCU400, OCU200 is in the preclinical stage, where it is undergoing testing for efficacy and safety to pave the way for future clinical trials.
3. Small Molecule Candidates:
Ocugen is advancing various small molecule candidates through its research and development pipeline. These include treatments not only for dry eye disease and glaucoma but also for a spectrum of other ocular conditions. The precise mechanisms of action for these small molecules are tailored to target the intricate pathways involved in each disease process to maximize therapeutic effects.
4. Research and Development Services:
In addition to its proprietary therapeutic candidates, Ocugen provides comprehensive research and development services aimed at partnering with other organizations. These services can range from preclinical development and clinical trial management to regulatory assistance and manufacturing solutions, facilitating the overall drug development process for both internal and external projects.
Conclusion
Ocugen Inc. stands out in the biopharmaceutical landscape with its focused approach to addressing rare and challenging ocular diseases through gene therapies, biologics, and small molecules. With innovative product candidates and supportive services, Ocugen is committed to improving patient outcomes and pioneering advancements in ocular health. As advancements in their development pipeline continue to progress, Ocugen remains dedicated to meeting the significant unmet needs within the field of ophthalmology.